BMO Stock Recent News
BMO LATEST HEADLINES
NEW YORK , Oct. 3, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Bank of Montreal ("BoM" or the "Company") (NYSE: BMO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
CAMBRIDGE, Mass., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced management's participation in investor meetings at the BMO Oncology Summit being held Tuesday, October 8, 2024, in New York, NY. With an initial focus in oncology, Foghorn's Gene Traffic Control® platform and resulting broad pipeline have the potential to transform the lives of people suffering from a wide spectrum of diseases.
NEW YORK, NY / ACCESSWIRE / September 29, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Bank of Montreal ("BoM" or the "Company") (NYSE: BMO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
NEW YORK, NY / ACCESSWIRE / September 27, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Bank of Montreal ("BoM" or the "Company") (NYSE:BMO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
NORWOOD, Mass., Sept. 26, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that the Company will participate in BMO Capital Markets' Oncology Summit, to be held October 8, 2024 in New York, NY. Dr. Dominic Smethurst, MA MRCP, Chief Medical Officer of Corbus, will participate in a panel titled Capitalizing on Validated Mechanism in Oncology. Dr. Smethurst will also be joined by Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, to participate in one-on-one investor meetings.
NEW YORK , Sept. 25, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Bank of Montreal ("BoM" or the "Company") (NYSE: BMO).
NEW YORK, NY / ACCESSWIRE / September 19, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Bank of Montreal ("BoM" or the "Company") (NYSE:BMO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
NEW YORK , Sept. 17, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Bank of Montreal ("BoM" or the "Company") (NYSE: BMO).
NEW YORK, NY / ACCESSWIRE / September 15, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Bank of Montreal ("BoM" or the "Company") (NYSE:BMO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
NEW YORK, NY / ACCESSWIRE / September 13, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Bank of Montreal ("BoM" or the "Company") (NYSE:BMO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.